Study of ION717 for early-stage prion disease
Part of Brain & nervous system, Infections clinical trials.
This trial tests an investigational drug called ION717 in people with early-stage prion disease. The goal is to see if it is safe and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of probable or definite prion disease.
- Your prion disease should be in the early stage when you join the study.
- You need a caregiver who is at least 18 years old and can help you during the trial.
- You must be willing to travel to the study center and complete all study visits and tests.
- You cannot have other serious medical conditions or be unable to have an MRI scan.
- You must be 18 years or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an RNA-based drug designed to turn off the gene that causes prion disease. It aims to see if the drug is safe in people with early-stage symptoms.
This study looks for early signs of prion disease in people who are at risk, using blood tests, spinal fluid, and thinking tests. It hopes to find ways to diagnose and track the disease earlier.
This trial tests an experimental drug called ION283, given by a lumbar puncture (spinal tap), to see if it is safe and can help with Lafora disease symptoms. It is for patients aged 10 to 18 with a confirmed genetic diagnosis.
This trial is testing an experimental drug (ION356) given by a lumbar puncture to see if it is safe and how it works in boys with Pelizaeus Merzbacher disease (PMD). The drug is designed to target the genetic cause of PMD.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.
Hear when a new Prion Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.